Sobre este episodio
Rapha, João e Fred discutem sobre a variante Omicron. O episódio é dividido em 3 partes: primeiro a discussão sobre as mudanças nas orientações de isolamento do Ministério da Saúde, segundo sobre a vacinação de reforço e a resposta vacinal com a nova variante, terceiro sobe os novos tratamentos de COVID-19 ambulatorial e atualizações sobre o tratamento hospitalar. Dá uma olhada nas "show notes" no nosso site tadeclinicagem.com.br Referências: Guia de Vigilância Epidemiológica Emergência de Saúde Pública de Importância Nacional pela Doença pelo Coronavírus 2019 (Ministério da Saúde, janeiro de 2022) Uptodate Jan 2022. COVID-19: Vaccines. Kathryn M Edwards,Walter A Orenstein, Martin S Hirsch, Allyson Bloom, MD. ACCORSI, Emma K. et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA, 2022. OMER, Saad B.; MALANI, Preeti N. Booster Vaccination to Prevent COVID-19 in the Era of Omicron: An Effective Part of a Layered Public Health Approach. JAMA, 2022. JOHNSON, Amelia G. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence—25 US Jurisdictions, April 4–December 25, 2021. MMWR. Morbidity and Mortality Weekly Report, v. 71, 2022. THOMPSON, Mark G. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance—VISION Network, 10 States, August 2021–January 2022. MMWR. Morbidity and Mortality Weekly Report, v. 71, 2022. NEMET, Ital et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. New England Journal of Medicine, 2021. SIGAL, Alex. Milder disease with Omicron: is it the virus or the pre-existing immunity?. Nature Reviews Immunology, p. 1-3, 2022. CLEMENS, Sue Ann Costa et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. The Lancet, 2022. GOTTLIEB, Robert L. et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. New England Journal of Medicine, 2021. KAWANO-DOURADO, Leticia; ROCHWERG, Bram. Therapeutics and COVID-19: living guideline. 2021. https://www.gov.br/anvisa/pt-br/assuntos/paf/coronavirus/medicamentos (acesso em 27/01/2022) CAO, Yunlong Richard et al. B. 1.1. 529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. BioRxiv, 2021. RAMACCIOTTI, Eduardo et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The Lancet, 2021. GUPTA, Anil et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. New England Journal of Medicine, v. 385, n. 21, p. 1941-1950, 2021. JAYK BERNAL, Angélica et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. New England Journal of Medicine, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results Rhee, C., et al. "Duration of SARS-CoV-2 infectivity: when is it safe to discontinue isolation?[manuscript published online ahead of print August 25 2020]." Clin Infect Dis (2020). Owusu, Daniel, et al. "Persistent SARS-CoV-2 RNA Shedding without Evidence of Infectiousness: A Cohort Study of Individuals with COVID-19." The Journal of Infectious Diseases (2021).
